UNSPSC 51181539: Gliamilide

This classification denotes an anti-diabetic agent with the molecular formula C23H33N5O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OTY52EM5B2, chemically known as 3-pyridinecarboxamide, n-(2-(1-(((((bicyclo(2.2.1)-hept-5-en-2-ylmethyl)amino)carbonyl)amino)sulfonyl)-4-piperidinyl)ethyl)-2-methoxy-, endo but generally known as gliamilide, which bears US NIH Compound Identifier 3037231. European Medicines Agency schedules Gliamilide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07915MIG.

UNSPSC 51181539 Gliamilide is a Commodity code for a sulfonylurea antidiabetic pharmaceutical, but state and local procurement activity under this specific code is not present in the available recent opportunities dataset. The code nominally covers gliamilide tablets or other formulations used in diabetes management, but public sector solicitations for individual active pharmaceutical ingredients at this granular level are extremely rare; state and local health agencies, correctional departments, and school districts typically procure diabetes medications through broader pharmaceutical supply contracts, group purchasing organizations, or generic drug catalogs rather than through discrete RFPs for named compounds.

No representative recent opportunities under UNSPSC 51181539 are documented in the current dataset, and no issuing bodies, geographic regions, notice types, or response dates can be identified for this code. Procurement professionals evaluating activity here should expect minimal or no direct bid opportunities at the gliamilide level; relevant work more commonly appears under higher-tier pharmaceutical supply codes (such as UNSPSC 51181500 Antidiabetic agents, or even broader Family-level codes covering managed pharmaceutical procurement) or through cooperative purchasing agreements with vendors specializing in hospital, clinic, or corrections pharmacy supply.